Abstract 3846
Background
Primary cancers of the appendix are rare and are frequently diagnosed after surgery for appendicitis. There is no designated staging system or evidence-based guideline for treatment. The staging and treatment of appendiceal adenocarcinoma mirror that of colon cancer. Elevated serum carcinoembryonic antigen (CEA) has been strongly associated with poor prognosis in colorectal cancer, so our study aims to first compare appendiceal cancers with tumors of the ascending colon, and then evaluate the prognostic value of CEA in appendiceal cancers.
Methods
We performed a retrospective analysis of all patients (n = 2,614) diagnosed with appendiceal adenocarcinoma from 2004 to 2014 in the National Cancer Institute’s Surveillance, Epidemiology and End Results database. All appendiceal cancer patients were designated as either elevated (C1) or normal (C0) based on the pretreatment serum CEA level. We performed univariate and multivariate analyses to compare appendiceal cancer characteristics to tumors of the ascending colon (n = 73,057), then identified independent factors associated with CEA elevation in appendiceal cancers.
Results
Upon multivariate analysis, compared to tumors of the ascending colon, appendiceal cancers are significantly more likely (P < 0.05) to have higher stage at diagnosis (OR 2.95, 1.19, 6.56 for stage 2, 3, and 4). They are less likely to have the CEA test ordered (OR 0.31). Appendiceal cancers are being diagnosed more in recent years (OR 1.90, 2.11, 1.86 for years 2012, 2013, and 2014) while colon cancer incidence is remaining the same. Compared to C0 appendiceal cancers, C1 cancers are more likely to have higher tumor grade (OR 6.56 and 5.50 for grade 2 and 3) and higher overall stage (OR 1.96, 2.44, 9.60 for stage 2, 3, and 4).
Conclusions
Though appendiceal cancers are rare, they are increasing in incidence. They are less likely than colorectal cancers to have the CEA test ordered despite CEA elevation odds ratio having no significant difference between the two cancers. Elevated CEA in appendiceal cancers is associated with later stage and higher grade. CEA levels should be checked in all appendiceal cancer patients to assist in the development of treatment strategies.
Clinical trial identification
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4403 - A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATForM)
Presenter: Jeffrey Weber
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4988 - Phase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- and RIG-1 agonist in patients with advanced solid tumors
Presenter: Patrick Terheyden
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5324 - ILLUMINATE 301: A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab (ipi) versus Ipi Alone in Subjects with Anti PD 1 Refractory Melanoma
Presenter: Paolo Ascierto
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4378 - Efficacy and safety of telotristat ethyl (TE) in combination with lanreotide (LAN) in patients with a neuroendocrine tumour and carcinoid syndrome (CS) diarrhoea (CSD): Meta-analysis of phase 3 double-blind placebo (PBO)-controlled TELESTAR and TELECAST studies
Presenter: Dieter Hörsch
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4484 - Development and internal validation of a predictive nomogram of progression-free survival in well-differentiated stage IV gastroenteropancreatic neuroendocrine tumours treated with somatostatin analogues: GETNE-TRASGU study.
Presenter: Rocio Garcia-Carbonero
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5321 - Impact of liver tumor burden on therapeutic effect of 177Lu-Dotatate treatment in NETTER-1 study
Presenter: Jonathan Strosberg
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4576 - Treatment outcomes for well differentiated grade 3 neuroendocrine tumors (NET G3)
Presenter: Leonidas Apostolidis
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5308 - Carboplatin (CB) combined with oral or intravenous (IV) etoposide (ET) for advanced extra-pulmonary (EP) poorly differentiated (PD) neuroendocrine carcinoma (NEC); real-world findings from two European Neuroendocrine Tumour Society Centres of Excellence.
Presenter: Melissa Frizziero
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5690 - Post-hoc analysis of CLARINET phase III study to investigate the influence of diabetic status on progression-free survival (PFS) of patients with neuroendocrine tumours (NETs) treated with lanreotide (LAN) or placebo (PBO)
Presenter: Sara Pusceddu
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5878 - The Prognostic Role of Morphology and Ki67 in Grade 3 Gastroenteropancreatic (GEP) Neuroendocrine Neoplasms (NEN)
Presenter: Aimee Hayes
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract